Over two decades have passed since posterior reversible encephalopathy syndrome (PRES) was first described in 1996. It has becoming increasingly recognised because of improved and more readily available imaging modality. The exact pathophysiological mechanism is not completely understood and remains controversial at present. Precise diagnosis is essential to guide prompt, proper management. Our ability of differentiating it from other acute neurological disorders is likely to improve as we learnt more about the spectrum of this entity in the last 20 years. We emphasise the importance of recognising its diagnostic criteria and biomarker, which would be of great relevance to either outcome evaluation or study design. PRES has a favourable prognosis generally, but neurological sequelae and even fatalities can occur, especially in severe forms that might cause substantial morbidity and even mortality, particularly when the syndrome is complicated by intracranial haemorrhage or brain infarction. In this review, the pathophysiology, approach to diagnosis, some controversies as to the prognosis, as well as the future research direction of PRES are described.
|Original language||English (US)|
|Number of pages||7|
|Journal||Journal of Neurology, Neurosurgery and Psychiatry|
|State||Published - Jan 1 2018|
Bibliographical noteFunding Information:
Funding BG reports research grant from National Natural Science Foundation of China (NSFC, Grant No. 81471645) and Shandong Provincial Key Research & Development Project (2015GSF118185).
© 2018 Article author(s). All rights reserved.
- imaging biomarker
- posterior reversible encephalopathy syndrome